RFRu Feng

Ru Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ru Feng has a total of 205 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaolei Wei

    Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Clinical Medical Research, Center of Hematology Diseases of Guangdong Province, Guangzhou, China

    10 shared publications
  • Yongqiang Wei

    Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    7 shared publications
  • Qi Wei

    Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    5 shared publications
  • Yongqiang Wei

    Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    4 shared publications
  • Fen Huang

    Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou Dadao North Street No. 1838, Guangzhou, 510515, China

    3 shared publications
  • Jingxia Zheng

    Department of Hematology, Nanfang Hospital, Southern Medical University or the First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China

    3 shared publications

Latest Publications

  • Prognostic Performance of the FLAMB Model in Primary Gastric Diffuse Large B-Cell Lymphoma

    by Jianbo Liu, Ao Li, Runhui Zheng, Haiying Wu, Yongqiang Wei, Ru Feng

    Aims/Background Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is a common gastrointestinal malignancy. While rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-based regimens have improved survival, reliable prognostic tools remain scarce. The International Prognostic Index (IPI), though validated for nodal DLBCL, shows limited accuracy in PG-DLBCL. To address this, we developed an intelligent prognostic model integrating key clinical variables to optimize individualized risk stratification, particularly for resource-limited clinical settings. Methods A retrospective cohort study was conducted at Nanfang Hospital, Southern Medical University, enrolling patients diagnosed with PG-DLBCL between January 2007 and July 2022. Clinical data and survival outcomes were systematically collected. Optimal cut-off values were systematically determined for continuous variables using receiver operating characteristic (ROC) curve analysis. Survival rates were estimated using the Kaplan-Meier method, with survival curves plotted and univariate survival associations assessed using the log-rank test. Multivariable analyses were performed through Cox proportional hazards regression and random forest algorithms. A novel (ferritin, lactate dehydrogenase (LDH), age, monocyte count (mono), β2-microglobulin (β2-MG)) FLAMB prognostic model was constructed by integrating the Cox regression model with random forest classification. Model performance was evaluated by comparing its discriminative accuracy with that of the IPI scoring system. Results Statistically significant differences in 5-year survival among PG-DLBCL patients were observed for ferritin, age, mono, LDH, β2-MG, B symptoms, and cell of origin (COO) in univariate survival analysis (p < 0.05). We developed the FLAMB model using five routinely available variables (ferritin, LDH, age, mono, and β2-MG) to enhance risk stratification in PG-DLBCL. Compared to the IPI, FLAMB demonstrated superior discriminative power (C-index: 0.653 vs. 0.637, Δ = 1.6%) and more effectively identified high-risk patients requiring treatment intensification. This enhanced risk stratification was confirmed by a statistically significant log-rank test (p < 0.05). Survival analysis in subgroups of non-germinal center B-cell like (GCB) and B symptoms-negative patients yielded consistent results. Conclusion The newly developed FLAMB prognostic model offers more precise prognostic stratification than the IPI for patients with PG-DLBCL. FLAMB comprises five key variables derived from routine laboratory tests and general clinical characteristics, making it readily accessible. This model enables clinicians, particularly in primary care or community hospitals, to efficiently stratify patient risk, assess underlying disease severity, and inform timely treatment planning.


  • Top Cited Papers
    Open Access

    Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

    by Jeff P. Sharman, Talha Munir, Sebastian Grosicki, Lindsey E. Roeker, John M. Burke, Christine I. Chen, Norbert Grzasko, George Follows, Zoltán Mátrai, Alessandro Sanna, et al.

    PURPOSE: Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III study conducted exclusively in patients with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with cBTKi, and compared pirtobrutinib with investigator's choice (IC) of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR). METHODS: Patients were randomly assigned 1:1 to receive pirtobrutinib (200 mg once daily) or IC of IdelaR or BR, and were stratified by previous use of venetoclax and del(17p). The primary end point was independent review committee–assessed progression-free survival (PFS). Secondary end points included time to next treatment or death (TTNT), overall survival (OS), and safety. The primary PFS end point was met at the time of the primary analysis (August 29, 2023), and updated results are reported from the final OS analysis (August 29, 2024). RESULTS: A total of 238 patients were randomly assigned to receive pirtobrutinib (n = 119) or IC (n = 119; IdelaR [n = 82], BR [n = 37]). The PFS hazard ratio (HR) was 0.54 ([95% CI, 0.39 to 0.75]; P = .0002), with a median PFS of 14 months (95% CI, 11.2 to 16.6) in the pirtobrutinib group and 8.7 months (95% CI, 8.1 to 10.4) with IC. The unadjusted OS HR was 1.09 ([95% CI, 0.68 to 1.75]; P = .7202), and 18-month OS rate was 73.4% (95% CI, 63.9 to 80.7) in the pirtobrutinib group and 70.8% (95% CI, 60.9 to 78.7) with IC. Median TTNT was 24 months (95% CI, 17.8 to 29.7) with pirtobrutinib versus 10.9 months (95% CI, 8.7 to 12.5) with IC (HR, 0.37 [95% CI, 0.25 to 0.52]). At a median follow-up of 17.2 months, grade ≥3 treatment-emergent adverse events (AEs) were lower with pirtobrutinib (57.7%) than IC (73.4%). Treatment discontinuation due to AE occurred in 20 (17.2%) patients receiving pirtobrutinib and 38 (34.9%) patients receiving IC. CONCLUSION: Pirtobrutinib improved PFS and TTNT, and demonstrated favorable tolerability, versus IdelaR/BR in exclusively cBTKi pretreated patients with CLL/SLL.


  • Open Access

    Low peripheral blood B lymphocyte count predicts poor outcome in patients with multiple myeloma

    by Yuqi Wang, Zhongxin Zheng, Qiaoxi Kang, Linjing Cai, Shanshan Zhang, Huan Chen, Youhai Yuan, Hanzhen Zhang, Xiaolei Wei, Ru Feng, et al.

  • Open Access

    Single‐Cell Multiomics Reveals TCR Clonotype‐Specific Phenotype and Stemness Heterogeneity of T‐ALL Cells

    by Songnan Sui, Xiaolei Wei, Yue Zhu, Qiuyue Feng, Xianfeng Zha, Lipeng Mao, Boya Huang, Wen Lei, Guobing Chen, Huien Zhan, et al.

    T‐cell acute lymphoblastic leukaemia (T‐ALL) is a heterogeneous malignant disease with high relapse and mortality rates. To characterise the multiomics features of T‐ALL, we conducted integrative analyses using single‐cell RNA, TCR and chromatin accessibility sequencing on pre‐ and post‐treatment peripheral blood and bone marrow samples of the same patients. We found that there is transcriptional rewiring of gene regulatory networks in T‐ALL cells. Some transcription factors, such as TCF3 and KLF3, showed differences in activity and expression levels between T‐ALL and normal T cells and were associated with the prognosis of T‐ALL patients. Furthermore, we identified multiple malignant TCR clonotypes among the T‐ALL cells, where the clonotypes consisted of distinct combinations of the same TCR α and β chain per patient. The T‐ALL cells displayed clonotype‐specific immature thymocyte cellular characteristics and response to chemotherapy. Remarkably, T‐ALL cells with an orphan TCRβ chain displayed the strongest stemness and resistance to chemotherapy. Our study provided transcriptome and epigenome characterisation of T‐ALL cells categorised by TCR clonotypes, which may be helpful for the development of novel predictive markers to evaluate treatment effectiveness for T‐ALL.


  • Open Access

    Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial

    by Zhiming Li, Wenqi Jiang, Hui Zhou, Hong Cen, Mingzhi Zhang, Fangfang Lv, Qingyuan Zhang, Xiuhua Sun, Lihong Liu, Yunhong Huang, et al.

    Background: In patients with untreated CD20-positive diffuse large B-cell lymphoma (DLBCL), a phase 3 trial was carried out to evaluate the efficacy and safety of zuberitamab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; Hi-CHOP) versus rituximab plus CHOP (R-CHOP) treatment regimens. Methods: In a 2:1 ratio, eligible patients were assigned randomly to receive treatment of six cycles of either 375 mg/m2 zuberitamab or rituximab together with conventional CHOP chemotherapy. The objective response rate (ORR) at C6D50 served as the primary endpoint, and a non-inferiority margin of 10% was established. The secondary endpoints included the complete response (CR) rate at C6D50, duration of response (DOR), progression-free survival (PFS) and event-free survival (EFS) judged by blinded-independent review committee (BIRC), overall survival (OS) and safety outcomes. Results: Of the 487 randomized patients, 423 patients including 287 in the Hi-CHOP and 136 in the R-CHOP groups completed the C6D50 assessment. For the full analysis set (FAS) and per-protocol set (PPS), BIRC-assessed ORR at C6D50 for the Hi-CHOP and R-CHOP groups were 83.5% versus 81.4% and 95.3% versus 93.7%, respectively. The non-inferiority was confirmed as the lower limit of the two-sided 95% CI for the intergroup differences of −5.2% and −3.3%; both were >−10% in the FAS and PPS. The BIRC-assessed CR rate of Hi-CHOP was significantly higher in PPS (85.7% vs 77.3%, p=0.038), but comparable in FAS (75.2% vs 67.9%, p=0.092). After a median follow-up of 29.6 months, patients in the Hi-CHOP group had a slight advantage with regard to the DOR (HR 0.74, p=0.173), PFS (HR 0.67, p=0.057), EFS (HR 0.90, p=0.517) and OS (HR 0.60, p=0.059). Patients with the germinal-center B cell-like subtype who received Hi-CHOP exhibited statistically significant improvements in ORR (p=0.034) and CR rate (p=0.038) at C6D50, EFS (p=0.046) and OS (p=0.014). Treatment-emergent adverse event occurrence rates were comparable across groups (all p>0.05). Infusion-related responses occurred more often in the Hi-CHOP group (32.1% vs 19.9%, p=0.006), all of grade 1–3 severity. Conclusions: Zuberitamab (375 mg/m2) plus CHOP was non-inferior to R-CHOP regarding ORR but exhibited a higher CR rate and was well tolerated in CD20-positive, previously untreated Chinese patients with DLBCL. Trial registration number: Chinese Clinical Trial Registry, ChiCTR2000040602, retrospectively registered.


  • Metabolic tumor volume from baseline [18 F]FDG PET/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma

    by Hanzhen Zhang, Zihan Xu, Wenlan Zhou, Junjie Chen, Yongqiang Wei, Hubing Wu, Xiaolei Wei, Ru Feng

    Purpose: Although several different parameters of PET/CT were reported to be predictive of survival in DLBCL, the best parameter remains to be elucidated and whether it could improve the risk stratification of IPI in patients with DLBCL. Procedures: 262 DLBCL patients including in the training and validation cohort were retrospectively analyzed in this study. Results: Among different parameters, MTV was identified as the optimal prognostic parameter with a maximum area under the curve (AUC) of 0.652 ± 0.112 than TLG and SDmax (0.645 ± 0.113 and 0.600 ± 0.117, respectively). Patients with high MTV were associated with inferior PFS (p < 0.001 and p = 0.021, respectively) and OS (p < 0.001 and p < 0.001, respectively) in both the training and validation cohort. The multivariate analysis revealed that high MTV was an unfavorable factor for PFS (relative ratio [RR], 2.295; 95% confidence interval [CI], 1.457–3.615; p < 0.01) and OS (RR, 2.929; 95% CI 1.679–5.109; p < 0.01) independent of IPI. Conclusions: Further analysis showed MTV could improve the risk stratification of IPI for both PFS and OS (p < 0.01 and p < 0.01, respectively). In conclusion, our study suggests that MTV was an optimal prognostic parameter of PET/CT for survival and it could improve the risk stratification of IPI in DLBCL, which may help to guide treatment in clinical trial.


  • Open Access

    Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma

    by Dan Xiong, Xiaolei Wei, Weiming Huang, Jingxia Zheng, Ru Feng

    Background/Aims: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, has significant prognostic heterogeneity. This study aimed to generate a prognostic prediction model based on autophagy-related genes for DLBCL patients. Methods: Utilizing bioinformatics techniques, we analyzed the clinical information and transcriptome data of DLBCL patients from the Gene Expression Omnibus (GEO) database. Through unsupervised clustering, we identified new autophagy-related molecular subtypes and pinpointed differentially expressed genes (DEGs) between these subtypes. Based on these DEGs, a prognostic model was constructed using Cox and Lasso regression. The effectiveness, accuracy, and clinical utility of this prognostic model were assessed using numerous independent validation cohorts, survival analyses, receiver operating characteristic (ROC) curves, multivariate Cox regression analysis, nomograms, and calibration curves. Moreover, functional analysis, immune cell infiltration, and drug sensitivity analysis were performed. Results: DLBCL patients with different clinical characterizations (age, molecular subtypes, ECOG scores, and stages) showed different expression features of autophagy-related genes. The prediction model was constructed based on the eight autophagy-related genes (ADD3, IGFBP3, TPM1, LYZ, AFDN, DNAJC10, GLIS3, and CCDC102A). The prognostic nomogram for overall survival of DLBCL patients incorporated risk level, stage, ECOG scores, and molecular subtypes, showing excellent agreement between observed and predicted outcomes. Differences were noted in the proportions of immune cells (native B cells, Treg cells, CD8+ T cell, CD4+ memory activated T cells, gamma delta T cells, macrophages M1, and resting mast cells) between high-risk and low-risk groups. LYZ and ADD3 exhibited correlations with drug resistance to most chemotherapeutic drugs. Conclusions: This study established a novel prognostic assessment model based on the expression profile of autophagy-related genes and clinical characteristics of DLBCL patients, explored immune infiltration and predicted drug resistance, which may guide precise and individualized immunochemotherapy regimens.


  • Open Access

    Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

    by Yuqin Song, Keshu Zhou, Shenmiao Yang, Jianda Hu, Dehui Zou, Sujun Gao, Ling Pan, Tingyu Wang, Haiyan Yang, Huilai Zhang, et al.

    Summary: We conducted two indirect comparisons to estimate the efficacy of zanubrutinib versus orelabrutinib in Chinese patients with relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or R/R mantle cell lymphoma (MCL). An unanchored matching-adjusted indirect comparison (MAIC) was performed in R/R CLL/SLL patients. Individual patient data from zanubrutinib trial (BGB-3111-205) were adjusted to match the aggregated data from the orelabrutinib trial (ICP-CL-00103). A naïve comparison was performed in R/R MCL for the different response assessment methodology and efficacy analysis set between the zanubrutinib (BGB-3111-206) and orelabrutinib (ICP-CL-00102) trials. Efficacy outcomes included ORR and PFS. In R/R CLL/SLL patients, after matching, IRC-assessed ORR was comparable (86.6% vs. 92.5%; risk difference, -5.9% [95% CI: -15.8%-3.8%]); IRC-assessed PFS was similar with a favorable trend in zanubrutinib over orelabrutinib (HR, 0.74 [95% CI: 0.37-1.47]) and the 18-month PFS rate was numerically higher in zanubrutinib (82.9% vs. 78.7%). In R/R MCL patients, naïve comparison showed investigator-assessed ORR was similar (83.7% vs. 87.9%; risk difference, -4.2% [95% CI: -14.8%-6.0%]), and CR rate was significantly higher in zanubrutinib over orelabrutinib (77.9% vs. 42.9%; risk difference, 35.0% [95% CI: 14.5%, 53.7%]). Investigator-assessed PFS was similar with a favorable trend (HR, 0.77 [95% CI: 0.45-1.32]) in zanubrutinib over orelabrutinib and the 12-month PFS rate was numerically higher in zanubrutinib (77.5% vs. 70.8%). MAIC result showed zanubrutinib demonstrated favorable PFS over orelabrutinib for R/R CLL/SLL patients. The naïve comparison showed zanubrutinib had favorable PFS and higher CR rate than orelabrutinib for R/R MCL patients.


  • Open Access

    Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity

    by Yuankun Zhang, Qingxiao Song, Kaniel Cassady, Michael Lee, Haidong Tang, Moqian Zheng, Bixin Wang, Dustin E. Schones, Yang-Xin Fu, Arthur D. Riggs, et al.

    PD-L1 has two receptors: PD-1 and CD80. Previous reports assumed that PD-L1 and CD80 interacted in trans, but recent reports showed that only cis PD-L1/CD80 interactions existed, and prevention of cis PD-L1/CD80 interactions on antigen-presenting cells (APCs) reduced antitumor immunity via augmenting PD-L1/PD-1 and CD80/CTLA4 interactions between T and APCs. Here, using tumor-bearing mice capable of cis and trans or trans only PD-L1/CD80 interactions, we show that trans PD-L1/CD80 interactions do exist between tumor and T cells, and the effects of trans PD-L1/CD80 interactions require tumor cell expression of MHC-I and T cell expression of CD28. The blockade of PD-L1/CD80 interactions in mice with both cis and trans interactions or with only trans interactions augments antitumor immunity by expanding IFN-γ–producing CD8 + T cells and IFN-γ–dependent NOS2-expressing tumor-associated macrophages. Our studies indicate that although cis and trans PD-L1/CD80 interactions may have opposite effects on antitumor immunity, the net effect of blocking PD-L1/CD80 interactions in vivo augments CD8 + T cell-mediated antitumor immunity.


  • CD43 is an adverse prognostic factor in newly diagnosed multiple myeloma

    by Xueqin Ning, Xiaolei Wei, Bingyuan Chen, Zhen Li, Zhongxin Zheng, Zhengshan Yi, Qi Wei, Xutao Guo, Qiaoxi Kang, Ru Feng, et al.

    Currently, the expression pattern and prognostic value of CD43 expression in multiple myeloma (MM) remain unknown. 109 newly diagnosed MM patients were recruited and CD43 expression was determined by multiparameter flow cytometry, of which 77 (70.6%) were CD43 positive. Patients with positive CD43 expression were more likely to present with, hemoglobin < 85 g/L (p = 0.008), International Staging System (ISS) stage III (p = 0.044), 13q14 deletion (p = 0.034) and more monoclonal plasma cells (p = 0.003). Patients with CD43 positive had significantly poor treatment response (p = 0.021), progression-free survival (PFS) (p = 0.012), and overall survival (OS) (p = 0.023) than those without CD43. The poorer prognosis of CD43-positive patients was retained in multivariate analysis (p = 0.005 for PFS; p = 0.013 for OS). Our study indicated that CD43 was an independent adverse prognostic factor in multiple myeloma.